Drug Profile
KDT 3594
Alternative Names: AM006; KDT-3594Latest Information Update: 27 May 2022
Price :
$50
*
At a glance
- Originator Kissei Pharmaceutical
- Developer AffaMed Therapeutics; Kissei Pharmaceutical
- Class Antiparkinsonians
- Mechanism of Action Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Parkinson's disease
Most Recent Events
- 06 Sep 2021 Kissei Pharmaceutical completes a phase II trial in Parkinson's disease (In adults, In elderly) in Japan (PO) (NCT04867551)
- 04 Aug 2021 Phase-II clinical trials in Parkinson's disease in China (PO) (Kissei Pharmaceutical pipeline, August 2021)
- 27 May 2021 China's National Medical Products Administration approves Clinical Trial Application for KDT 3594 in Parkinson's Disease